GLS2 and leukemia: Novel L-asparaginases tested in this study (EcAIII, KpAIII, and ReAIV) are free of L-glutaminase co-activity; therefore, their potential application in leukemia therapy will prevent the occurrence of side effects related to L-Gln depletion.